Agenus shared on LinkedIn:
“Agenus today reported second quarter 2026 financial results and provided an update on its strategy to advance BOT+BAL in neoadjuvant MSS colon cancer through the Phase 3 ROBBIN trial, supported by continued patient access and strengthened financial resources.”
Other articles about colon cancer on OncoDaily.
